Cencora backs FY26 adjusted EPS view $17.45-$17.75, consensus $17.67

Backs FY26 revenue growth view 5%-7% vs. FY25 revenue $321.3B. FY26 consensus $340.56B. The company said, “To reflect Cencora’s (COR) expectations for continued growth and execution, the Company is reiterating its fiscal 2026 consolidated guidance. In anticipation of the Company’s acquisition of OneOncology, it is pausing share repurchases, and therefore, it is more likely the Company’s full year adjusted diluted EPS will be towards the lower half of its guidance range of $17.45 to $17.75.”